Pure Global
NCT05817799

Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

Bahria University·Phase 2/3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hemodialysis Complication
Drug/Device/Intervention
L-Carnitine 500Mg thrice daily
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bahria University
Location
Karachi, Pakistan
Timeline & enrollment
Phase
Phase 2/3
Start date
Jan 01, 2023
End date
Jul 10, 2023
Enrollment
83 participants
Primary outcome

L-Carnitine levels in hemodialysis

Summary

OBJECTIVES
 
 - To assess the levels of plasma carnitine in controls and hemodialysis patients.
 
 - To give supplementary L-carnitine to study subjects for a duration of 5months.
 
 - To compare the values of plasma carnitine before and after L carnitine supplementation.
 
 - To assess the role of carnitine supplementation on biochemical and clinical parameters.

ICD-10 classifications
Kidney dialysisOther dialysisCare involving dialysisMechanical complication of vascular dialysis catheterHaemoglobinuria due to haemolysis from other external causes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05817799
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05817799 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Bahria University and is currently Recruiting. The study focuses on Hemodialysis Complication. Target enrollment is 83 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.